Postpartum Hemorrhage Up With Specific Antidepressants

Share this content:
Postpartum Hemorrhage Up With Specific Antidepressants
Postpartum Hemorrhage Up With Specific Antidepressants

TUESDAY, Feb. 9, 2016 (HealthDay News) -- Exposure to serotonin-norepinephrine reuptake inhibitors in late pregnancy is associated with increased risk of postpartum hemorrhage, according to a study published in the March issue of Obstetrics & Gynecology.

Gillian E. Hanley, Ph.D., from the University of British Columbia in Vancouver, Canada, and colleagues conducted a population-based cohort study involving 225,973 women with 322,224 pregnancies. The authors examined the correlation between exposure to selective serotonin reuptake inhibitors and selective serotonin-norepinephrine reuptake inhibitors in pregnancy and postpartum hemorrhage.

The researchers found that after adjustment for potential confounders, the risk of postpartum hemorrhage was increased with exposure to a serotonin-norepinephrine reuptake inhibitor in the final month of pregnancy (adjusted odds ratio [aOR], 1.76; 95 percent confidence interval [CI], 1.47 to 2.11), corresponding to 4.1 additional cases of postpartum hemorrhage per 100 people treated. No correlation was seen between selective serotonin reuptake inhibitor use in the final month of pregnancy and postpartum hemorrhage (aOR, 1.09; 95 percent CI, 0.98 to 1.21), apart from when the cohort was limited to women with complete body mass index (BMI) information and adjusted for BMI (aOR, 1.14; 95 percent CI, 1.01 to 1.28) or after adjustment for variables that may be on the causal pathway (aOR, 1.13; 95 percent CI, 1.02 to 1.26).

"Women and their physicians should be aware of potential risks associated with serotonin-norepinephrine reuptake inhibitor use near the end of pregnancy," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »